FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3018507461> ?p ?o ?g. }

• W3018507461 endingPage "e202" @default.
• W3018507461 startingPage "e194" @default.
• W3018507461 abstract "Aims Intrahepatic progression remains the predominant mode of cancer-related death in hepatocellular carcinoma (HCC) underscoring the need for effective local therapies. We report our initial experience with liver stereotactic body radiotherapy (SBRT) in the management of early to advanced stage HCC at an Australian tertiary liver cancer service. Materials and methods Patients with liver-confined HCC unsuitable for surgical resection or thermal ablation treated with SBRT between October 2013 and December 2018 were retrospectively evaluated. The primary end point was freedom from local progression. Secondary end points were progression-free survival, disease-specific survival, overall survival and toxicity. Results Ninety-six patients were treated for 112 lesions (median size 3.8 cm, range 1.5–17 cm). The median follow-up was 13 months (range 3–65). Forty-six patients had received prior local therapies (median 1, range 1–5), 83 (86%) patients had cirrhosis with baseline Child–Pugh scores of A (88%) and B7–8 (12%). Fifty-nine (61%) patients had Barcelona Clinic Liver Cancer (BCLC) stage 0/A disease and 37 (39%) had stage B/C. Macrovascular invasion was present in 20 (21%). The median biologically effective dose (BED10) was 86 and 60 Gy for the BCLC 0/A and B/C cohorts, respectively. Freedom from local progression at 18 months was 94% for BCLC 0/A and 74% for BCLC B/C. Progression-free survival and overall survival at 12 months were 80 and 95% for BCLC 0/A and 40 and 71% for BCLC B/C, respectively. Five patients (7%) with cirrhosis and without disease progression had an increase in Child–Pugh score >1 within 3 months of SBRT, four of whom had intercurrent infections. Clinical toxicities grade ≥2 were reported in 20% of patients. Conclusion SBRT is an effective ablative modality for early stage HCC with low rates of significant toxicity. Lower dose SBRT can provide durable local control for advanced stage HCC. However, out-of-field relapse remains common, providing a rationale to investigate SBRT in combination with other therapies." @default.
• W3018507461 created "2020-05-01" @default.
• W3018507461 creator A5002581018 @default.
• W3018507461 creator A5022895164 @default.
• W3018507461 creator A5023269409 @default.
• W3018507461 creator A5036603812 @default.
• W3018507461 creator A5040559812 @default.
• W3018507461 creator A5055591728 @default.
• W3018507461 creator A5064447706 @default.
• W3018507461 creator A5068831437 @default.
• W3018507461 creator A5072890476 @default.
• W3018507461 date "2020-10-01" @default.
• W3018507461 modified "2023-10-18" @default.
• W3018507461 title "Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma – Initial Experience From an Australian Liver Cancer Service" @default.
• W3018507461 cites W1535977601 @default.
• W3018507461 cites W1606647501 @default.
• W3018507461 cites W1963802272 @default.
• W3018507461 cites W1966475629 @default.
• W3018507461 cites W1981779460 @default.
• W3018507461 cites W1983433361 @default.
• W3018507461 cites W1987659344 @default.
• W3018507461 cites W2036138137 @default.
• W3018507461 cites W2093274439 @default.
• W3018507461 cites W2107082158 @default.
• W3018507461 cites W2133685049 @default.
• W3018507461 cites W2163403599 @default.
• W3018507461 cites W2170366300 @default.
• W3018507461 cites W2185023695 @default.
• W3018507461 cites W2221304580 @default.
• W3018507461 cites W2277004004 @default.
• W3018507461 cites W2591184874 @default.
• W3018507461 cites W2736204246 @default.
• W3018507461 cites W2753536696 @default.
• W3018507461 cites W2761031851 @default.
• W3018507461 cites W2791082369 @default.
• W3018507461 cites W2885700523 @default.
• W3018507461 cites W2889996283 @default.
• W3018507461 cites W2890715773 @default.
• W3018507461 cites W2892501818 @default.
• W3018507461 cites W2906772125 @default.
• W3018507461 cites W2908469182 @default.
• W3018507461 cites W2916608345 @default.
• W3018507461 cites W2949136994 @default.
• W3018507461 cites W2955692127 @default.
• W3018507461 cites W2969389433 @default.
• W3018507461 cites W4210955410 @default.
• W3018507461 cites W808471657 @default.
• W3018507461 doi "https://doi.org/10.1016/j.clon.2020.04.004" @default.
• W3018507461 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32345457" @default.
• W3018507461 hasPublicationYear "2020" @default.
• W3018507461 type Work @default.
• W3018507461 sameAs 3018507461 @default.
• W3018507461 citedByCount "15" @default.
• W3018507461 countsByYear W30185074612020 @default.
• W3018507461 countsByYear W30185074612021 @default.
• W3018507461 countsByYear W30185074612022 @default.
• W3018507461 countsByYear W30185074612023 @default.
• W3018507461 crossrefType "journal-article" @default.
• W3018507461 hasAuthorship W3018507461A5002581018 @default.
• W3018507461 hasAuthorship W3018507461A5022895164 @default.
• W3018507461 hasAuthorship W3018507461A5023269409 @default.
• W3018507461 hasAuthorship W3018507461A5036603812 @default.
• W3018507461 hasAuthorship W3018507461A5040559812 @default.
• W3018507461 hasAuthorship W3018507461A5055591728 @default.
• W3018507461 hasAuthorship W3018507461A5064447706 @default.
• W3018507461 hasAuthorship W3018507461A5068831437 @default.
• W3018507461 hasAuthorship W3018507461A5072890476 @default.
• W3018507461 hasConcept C121608353 @default.
• W3018507461 hasConcept C126322002 @default.
• W3018507461 hasConcept C141071460 @default.
• W3018507461 hasConcept C143998085 @default.
• W3018507461 hasConcept C146357865 @default.
• W3018507461 hasConcept C151730666 @default.
• W3018507461 hasConcept C2776231280 @default.
• W3018507461 hasConcept C2776694085 @default.
• W3018507461 hasConcept C2777075537 @default.
• W3018507461 hasConcept C2777214474 @default.
• W3018507461 hasConcept C2778019345 @default.
• W3018507461 hasConcept C2780739268 @default.
• W3018507461 hasConcept C71924100 @default.
• W3018507461 hasConcept C86803240 @default.
• W3018507461 hasConcept C90924648 @default.
• W3018507461 hasConceptScore W3018507461C121608353 @default.
• W3018507461 hasConceptScore W3018507461C126322002 @default.
• W3018507461 hasConceptScore W3018507461C141071460 @default.
• W3018507461 hasConceptScore W3018507461C143998085 @default.
• W3018507461 hasConceptScore W3018507461C146357865 @default.
• W3018507461 hasConceptScore W3018507461C151730666 @default.
• W3018507461 hasConceptScore W3018507461C2776231280 @default.
• W3018507461 hasConceptScore W3018507461C2776694085 @default.
• W3018507461 hasConceptScore W3018507461C2777075537 @default.
• W3018507461 hasConceptScore W3018507461C2777214474 @default.
• W3018507461 hasConceptScore W3018507461C2778019345 @default.
• W3018507461 hasConceptScore W3018507461C2780739268 @default.
• W3018507461 hasConceptScore W3018507461C71924100 @default.
• W3018507461 hasConceptScore W3018507461C86803240 @default.
• W3018507461 hasConceptScore W3018507461C90924648 @default.
• W3018507461 hasIssue "10" @default.

• next